Basic Information
RNALocate ID: | RLID:01001285 |
RNA Symbol: | hsa-miR-19b-3p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-19b |
RNA ID: | miRBase:MIMAT0000074 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21695135 |
Tissue/Cell Line: | Cell line (HeLa) |
Method: | Microarray |
Heatmap showing the 57 miRNAs differentially expressed in HeLa cells from mitochondrial and cytosolic RNA. Three independent microarray profiling experiments (microarray n1, n2 and n3) are shown and reproducibly revealed 13 miRNAs enriched in mitochondrial RNA. Originally published in PLoS One. Bandiera S, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | While 44 miRNAs showed a greater enrichment in the cytosolic Hy3-labeled RNA fraction, 13 miRNAs were significantly and reproducibly enriched in the mitochondrial Hy5-labeled RNA sample (ranging from 1.5- to 56-fold), namely hsa-miR-1973, hsa-miR-1275, hsa-miR-494, hsa-miR-513a-5p, hsa-miR-1246, hsa-miR-328, hsa-miR-1908, hsa-miR-1972, hsa-miR-1974, hsa-miR-1977, hsa-miR-638, hsa-miR-1978 and hsa-miR-1201 (Figure 5A). Data are collected from Figure 5. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001283 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001284 | Cytoplasm | Colon cancer cells | 20864815 |
RLID:01001286 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001287 | Mitochondrion | Myotube | 27396686 |
RLID:01001288 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001289 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001290 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001291 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001292 | Nucleus | GC cell line (MGC-803) | 29872807 |
RLID:01001293 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11000724 | Exosome | Glioblastoma cells | 19011622 |
RLID:11000725 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000726 | Exosome | Renal cancer cells | 21670082 |
RLID:11000727 | Exosome | Brain tissue | 23382797 |
RLID:11000728 | Exosome | Plasma | 23663360 |
RLID:11000729 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000730 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
RLID:11000731 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11000732 | Extracellular Vesicle | Liposarcoma cell lines (Lipo246|Lipo863|LPS141)|Preadipocytes | 28588009 |
RLID:11000733 | Microvesicle | Glioblastoma cells | 19011622 |
RLID:11000734 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000735 | Microvesicle | Follicular fluid | 23666971 |
RLID:11000736 | Microvesicle | Cerebrospinal fluid | 24797360 |
RLID-D:11000011 | Exosome | B lymphoblastoid cells|Breast milk|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
RLID-D:11000273 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-19b-3p | Diffuse large b cell lymphoma | MNDR-E-MI-25628 |
MNDR | hsa-miR-19b-3p | Mantle cell lymphoma | MNDR-E-MI-25629 |
MNDR | hsa-miR-19b-3p | Splenic marginal zone lymphoma | MNDR-E-MI-25630 |
MNDR | hsa-miR-19b-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-25631 |
MNDR | hsa-miR-19b-3p | Oral squamous cell carcinoma | MNDR-E-MI-25632 |
MNDR | hsa-miR-19b-3p | Large cell neuroendocrine cancer | MNDR-E-MI-25633 |
MNDR | hsa-miR-19b-3p | Medulloblastoma | MNDR-E-MI-25634 |
MNDR | hsa-miR-19b-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25635 |
MNDR | hsa-miR-19b-3p | Lymphoma | MNDR-E-MI-25636 |
MNDR | hsa-miR-19b-3p | Lymphoma non-hodgkin | MNDR-E-MI-25637 |
MNDR | hsa-miR-19b-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-25638 |
MNDR | hsa-miR-19b-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-25639 |
MNDR | hsa-miR-19b-3p | Her2-receptor positive breast cancer | MNDR-E-MI-25640 |
MNDR | hsa-miR-19b-3p | Niemann-pick disease type c | MNDR-E-MI-25641 |
MNDR | hsa-miR-19b-3p | Prostate cancer | MNDR-E-MI-25642 |
MNDR | hsa-miR-19b-3p | Gastric cancer | MNDR-E-MI-25643 |
MNDR | hsa-miR-19b-3p | Gastric lymphoma | MNDR-E-MI-25644 |
MNDR | hsa-miR-19b-3p | Alzheimer disease | MNDR-E-MI-25645 |
MNDR | hsa-miR-19b-3p | Encephalitis japanese | MNDR-E-MI-25646 |
MNDR | hsa-miR-19b-3p | Intracranial aneurysm | MNDR-E-MI-25647 |
MNDR | hsa-miR-19b-3p | Bladder cancer | MNDR-E-MI-25648 |
MNDR | hsa-miR-19b-3p | Sarcoma | MNDR-E-MI-25649 |
MNDR | hsa-miR-19b-3p | Dysautonomia familial | MNDR-E-MI-25650 |
MNDR | hsa-miR-19b-3p | Head and neck cancer | MNDR-E-MI-25651 |
MNDR | hsa-miR-19b-3p | Huntington disease | MNDR-E-MI-25652 |
MNDR | hsa-miR-19b-3p | Chorea | MNDR-E-MI-25653 |
MNDR | hsa-miR-19b-3p | Cardiovascular disease | MNDR-E-MI-25654 |
MNDR | hsa-miR-19b-3p | Carotid stenosis | MNDR-E-MI-25655 |
MNDR | hsa-miR-19b-3p | Moyamoya disease | MNDR-E-MI-25656 |
MNDR | hsa-miR-19b-3p | Lung cancer | MNDR-E-MI-25657 |
MNDR | hsa-miR-19b-3p | Fragile x syndrome | MNDR-E-MI-25658 |
MNDR | hsa-miR-19b-3p | Parkinson disease | MNDR-E-MI-25659 |
MNDR | hsa-miR-19b-3p | Machado-joseph disease | MNDR-E-MI-25660 |
MNDR | hsa-miR-19b-3p | Niemann-pick disease | MNDR-E-MI-25661 |
MNDR | hsa-miR-19b-3p | Basal-like breast cancer | MNDR-E-MI-25662 |
MNDR | hsa-miR-19b-3p | Squamous cell carcinoma | MNDR-E-MI-25663 |
MNDR | hsa-miR-19b-3p | Thyroid cancer | MNDR-E-MI-25664 |
MNDR | hsa-miR-19b-3p | Pancreatic cancer | MNDR-E-MI-25665 |
MNDR | hsa-miR-19b-3p | Malignant melanoma | MNDR-E-MI-25666 |
MNDR | hsa-miR-19b-3p | Atherosclerosis | MNDR-E-MI-25667 |
MNDR | hsa-miR-19b-3p | Rectum adenocarcinoma | MNDR-E-MI-25668 |
MNDR | hsa-miR-19b-3p | Nephroblastoma | MNDR-E-MI-25669 |
MNDR | hsa-miR-19b-3p | Colon cancer | MNDR-E-MI-25670 |
MNDR | hsa-miR-19b-3p | Ischemic attack transient | MNDR-E-MI-25671 |
MNDR | hsa-miR-19b-3p | Colon adenocarcinoma | MNDR-E-MI-25672 |
MNDR | hsa-miR-19b-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-25673 |
MNDR | hsa-miR-19b-3p | Familial ovarian cancer | MNDR-E-MI-25674 |
MNDR | hsa-miR-19b-3p | Basal cell carcinoma | MNDR-E-MI-25675 |
MNDR | hsa-miR-19b-3p | Prostate adenocarcinoma | MNDR-E-MI-25676 |
MNDR | hsa-miR-19b-3p | Kidney cancer | MNDR-E-MI-25677 |
MNDR | hsa-miR-19b-3p | Thyroid adenomas | MNDR-E-MI-25678 |
MNDR | hsa-miR-19b-3p | Carcinoma ductal breast | MNDR-E-MI-25679 |
MNDR | hsa-miR-19b-3p | Glioblastoma | MNDR-E-MI-25680 |
MNDR | hsa-miR-19b-3p | Astrocytoma | MNDR-E-MI-25681 |
MNDR | hsa-miR-19b-3p | Glioma | MNDR-E-MI-25682 |
MNDR | hsa-miR-19b-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-25683 |
MNDR | hsa-miR-19b-3p | Central nervous system lymphoma | MNDR-E-MI-25684 |
MNDR | hsa-miR-19b-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-25685 |
MNDR | hsa-miR-19b-3p | Osteosarcoma | MNDR-E-MI-25686 |
MNDR | hsa-miR-19b-3p | Liposarcoma | MNDR-E-MI-25687 |
MNDR | hsa-miR-19b-3p | Coronary artery disease | MNDR-E-MI-25688 |
MNDR | hsa-miR-19b-3p | Meningioma | MNDR-E-MI-25689 |
MNDR | hsa-miR-19b-3p | Liver cancer | MNDR-E-MI-25690 |
MNDR | hsa-miR-19b-3p | Cervical adenocarcinoma | MNDR-E-MI-25691 |
MNDR | hsa-miR-19b-3p | Gastric adenocarcinoma | MNDR-E-MI-25692 |
MNDR | hsa-miR-19b-3p | Cervical squamous cell carcinoma | MNDR-E-MI-25693 |
MNDR | hsa-miR-19b-3p | Lung squamous cell carcinoma | MNDR-E-MI-25694 |
MNDR | hsa-miR-19b-3p | Carcinoma lung non-small-cell | MNDR-E-MI-25695 |
MNDR | hsa-miR-19b-3p | Lung adenocarcinoma | MNDR-E-MI-25696 |
MNDR | hsa-miR-19b-3p | Thyroid carcinoma | MNDR-E-MI-25697 |
MNDR | hsa-miR-19b-3p | Bladder urothelial carcinoma | MNDR-E-MI-25698 |
MNDR | hsa-miR-19b-3p | Cervical cancer | MNDR-E-MI-25699 |
MNDR | hsa-miR-19b-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-25700 |
MNDR | hsa-miR-19b-3p | Carcinoma renal cell | MNDR-E-MI-25701 |
MNDR | hsa-miR-19b-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25702 |
MNDR | hsa-miR-19b-3p | Renal clear cell carcinoma | MNDR-E-MI-25703 |
MNDR | hsa-miR-19b-3p | Biliary tract cancer | MNDR-E-MI-25704 |
MNDR | hsa-miR-19b-3p | Cholangiocarcinoma | MNDR-E-MI-25705 |
MNDR | hsa-miR-19b-3p | Esophageal cancer | MNDR-E-MI-25706 |
MNDR | hsa-miR-19b-3p | Lung small cell carcinoma | MNDR-E-MI-25707 |
MNDR | hsa-miR-19b-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-25708 |
MNDR | hsa-miR-19b-3p | Encephalomyelitis | MNDR-E-MI-25709 |
MNDR | hsa-miR-19b-3p | Breast invasive carcinoma | MNDR-E-MI-25710 |
MNDR | hsa-miR-19b-3p | Hepatocellular carcinoma | MNDR-E-MI-25711 |
MNDR | hsa-miR-19b-3p | Familiar ovarian carcinoma | MNDR-E-MI-25712 |
MNDR | hsa-miR-19b-3p | B-cell lymphoma | MNDR-E-MI-25713 |
MNDR | hsa-miR-19b-3p | Rheumatoid arthritis | MNDR-E-MI-25714 |
MNDR | hsa-miR-19b-3p | T-cell leukemia | MNDR-E-MI-25715 |
MNDR | hsa-miR-19b-3p | Cervical carcinoma | MNDR-E-MI-25716 |
MNDR | hsa-miR-19b-3p | Retinoblastoma | MNDR-E-MI-25717 |
MNDR | hsa-miR-19b-3p | Neuroblastoma | MNDR-E-MI-25718 |
MNDR | hsa-miR-19b-3p | Hodgkin lymphoma | MNDR-E-MI-25719 |
MNDR | hsa-miR-19b-3p | Burkitt lymphoma | MNDR-E-MI-25720 |
MNDR | hsa-miR-19b-3p | Lymphosarcoma | MNDR-E-MI-25721 |
MNDR | hsa-miR-19b-3p | Crohn disease | MNDR-E-MI-25722 |
MNDR | hsa-miR-19b-3p | Intermediate coronary syndrome | MNDR-E-MI-25723 |
MNDR | hsa-miR-19b-3p | Tonsil cancer | MNDR-E-MI-25724 |
MNDR | hsa-miR-19b-3p | Acute myelogenous leukemia | MNDR-E-MI-25725 |
MNDR | hsa-miR-19b-3p | Colorectal cancer | MNDR-E-MI-25726 |
MNDR | hsa-miR-19b-3p | Nasopharyngeal carcinoma | MNDR-E-MI-25727 |
MNDR | hsa-miR-19b-3p | Nasopharynx carcinoma | MNDR-E-MI-25728 |
MNDR | hsa-miR-19b-3p | Multiple myeloma | MNDR-E-MI-25729 |
MNDR | hsa-miR-19b-3p | Carcinoid tumors intestinal | MNDR-E-MI-25730 |
MNDR | hsa-miR-19b-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-25731 |
MNDR | hsa-miR-19b-3p | Uterine cervical neoplasms | MNDR-E-MI-25732 |
MNDR | hsa-miR-19b-3p | Ependymoma | MNDR-E-MI-25733 |
MNDR | hsa-miR-19b-3p | Nasopharyngeal cancer | MNDR-E-MI-25734 |
MNDR | hsa-miR-19b-3p | Prostatic neoplasms | MNDR-E-MI-25735 |
MNDR | hsa-miR-19b-3p | Stroke lacunar | MNDR-E-MI-25736 |
MNDR | hsa-miR-19b-3p | Duke A | MNDR-E-MI-25737 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCB1 | Homo sapiens | RR00022778 |
TOP